GlassScriptPhysician profile
Sabrina N Scarbrough
NPI 1528723160
$883.66
in general payments reported to CMS, 2019-2025
21 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $77.48 · 2023: $112 · 2024: $266 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $224.17 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $143.82 | 2025 | |
| Merck Sharp & Dohme LLC | $106.75 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $50.97 | 2023-2024 | |
| Inspire Medical Systems, INC. | $45.97 | 2025 | Inspire |
| Pfizer INC. | $44.80 | 2024-2025 | |
| Lilly USA, LLC | $27.97 | 2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $27.05 | 2025 | Veozah |
| Abbvie INC. | $25.09 | 2023 | |
| Abiomed | $18.47 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.03 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.20 | 2023 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $15.97 | 2024 | Breztri |
| Ultragenyx Pharmaceutical INC. | $15.86 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $15.38 | 2022 | |
| Glaxosmithkline, LLC. | $14.60 | 2025 | Bexsero, Penmenvy |
| Novo Nordisk INC | $13.90 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.81 | 2024 | Opsumit, Uptravi |
| Neurocrine Biosciences, INC. | $13.68 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Scarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.